At ISMPP 2025, a clear imperative emerged: the future of medical publications reporting must be more inclusive, accessible, and patient-centered. Read the article here.

Artificial intelligence (AI) is rapidly influencing the future of medical publication development. Read about our findings in this article.

Our client was approaching the launch of a new product for treatment of a mental health disorder. Despite promising trial data, successful adoption of their therapy would be challenging for a number of reasons. Read the case study.

Learn how we guided our client through early-stage clinical trials and competitive pressures to craft a compelling scientific narrative. Read the case study.

Learn how we navigated the challenges of launching a novel treatment in a rare hematologic disease to position our client's drug as a potential new standard of care. Read the full case study.

Our biotech client was facing the challenge of introducing a new competitor into the market while simultaneously gaining a deeper understanding of their disease state. To navigate this complex scenario, they needed a strategic document that would serve as the foundation for both internal and external communications.

Our client, a leading biopharmaceutical company, sought to embark on a clinical development program within a new therapeutic area in the rare disease space. Read the case study.

A recent pivotal Phase 3 clinical trial marked a significant milestone for our client, a biopharmaceutical company, in their quest to introduce a novel treatment for major depressive disorder (MDD). Read more.